Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. develops masked immuno-oncology therapies for people living with cancer. Company news centers on its proprietary masking technology, which is designed to localize anti-tumor activity within the tumor microenvironment, and on pipeline updates for masked biologics and multi-specific I-O molecules.
Recurring developments include preclinical data for programs such as XTX601, a masked T cell engager targeting CLDN18.2, updates on XTX501, a bispecific PD-1 / masked IL-2 program, and disclosures involving masked T cell engager programs targeting PSMA and STEAP1. News also covers financial results, scientific conference presentations, inducement equity grants, board composition, and capital-structure actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.